ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)
dc.contributor.author | Felip, E. | en |
dc.contributor.author | Stahel, R. A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Felip, E. | en |
dc.creator | Stahel, R. A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:01Z | |
dc.date.available | 2018-06-22T09:53:01Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41613 | |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | European union | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Cancer survival | en |
dc.subject | Chemotherapy | en |
dc.subject | Drug response | en |
dc.subject | Follow up | en |
dc.subject | Neoplasm staging | en |
dc.subject | Platinum derivative | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical trial | en |
dc.subject | Gemcitabine | en |
dc.subject | Navelbine | en |
dc.subject | Taxane derivative | en |
dc.subject | Cancer staging | en |
dc.subject | Docetaxel | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Cancer mortality | en |
dc.subject | Carcinoma | en |
dc.subject | Adjuvant | en |
dc.subject | Risk assessment | en |
dc.subject | Cancer risk | en |
dc.subject | Histopathology | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Radiotherapy | en |
dc.subject | Risk factor | en |
dc.subject | Cancer incidence | en |
dc.subject | Smoking | en |
dc.subject | Bronchoscopy | en |
dc.subject | Diagnosis | en |
dc.subject | Incidence | en |
dc.subject | Pemetrexed | en |
dc.subject | Practice guideline | en |
dc.subject | Quality of life | en |
dc.subject | Medical society | en |
dc.subject | Differential | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Lung biopsy | en |
dc.subject | Lung surgery | en |
dc.subject | Postoperative care | en |
dc.title | ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC) | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdi821 | |
dc.description.volume | 16 | |
dc.description.issue | SUPPL. 1 | en |
dc.description.startingpage | i28 | |
dc.description.endingpage | i29 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |